Figure 6. Role of miR-216b in chemosensitivity of NSCLC cells to other platinum-based chemotherapeutic drugs.

(A) A549 and PC9 cells were transfected with miR-216b mimics (50 pmol/ml) followed by treatment with carboplatin (2 μM) or oxaliplatin (2 μM). MTT assay was performed to evaluate the cell viability. ^*P<0.05. (B) Effect of miR-216b mimics (50 pmol/ml) on changing IC50 of carboplatin and oxaliplatin to A549 and PC9 NSCLC cells. ^*P<0.05 vs. NCO group.